Glecaprevir/pibrentasvir for 8 weeks in non-cirrhotic and 12 weeks in cirrhotic patients is a highly efficacious and well-tolerated treatment for hepatitis C virus/human immunodeficiency virus-1 (HCV/HIV), a recent study found. This is regardless of baseline HCV viral load or prior treatment with interferon or sofosbuvir, according to results from EXPEDITION-2, a phase 3, multicenter, open-label study evaluating glecaprevir/pibrentasvir (300 mg/120 mg) in HCV genotype-1-6/HIV-1 coinfected adults with and without compensated cirrhosis for 8 and 12 weeks, respectively. Patients were either HCV treatment-naïve or experienced with sofosbuvir, ribavirin or interferon, and antiretroviral therapy (ART)-naïve or on a stable ART regimen for at least 8 weeks. The primary endpoint was the proportion of patients with sustained virologic response 12 weeks post-treatment (SVR12). Among the details:

• 153 patients were enrolled, including 16 (10%) with cirrhosis.
• SVR12 rate was 98% with no virologic failures in the 137 patients treated for 8 weeks.
• Most adverse events were mild.
• All patients treated with ART maintained HIV-1 suppression during treatment.